Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CEO Sanj Patel sold 151,300 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $94.71, for a total value of $14,329,623.00. Following the completion of the sale, the chief executive officer owned 774,500 shares in the company, valued at $73,352,895. This represents a 16.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Stock Performance
Shares of Kiniksa Pharmaceuticals International stock traded up $5.52 during trading hours on Friday, hitting $93.86. The company’s stock had a trading volume of 627,284 shares, compared to its average volume of 707,415. The stock has a market cap of $7.32 billion, a price-to-earnings ratio of 72.20 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48. The firm has a fifty day moving average of $80.18 and a 200-day moving average of $61.10.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
A number of hedge funds and other institutional investors have recently bought and sold shares of KNSA. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after purchasing an additional 421,347 shares during the period. Pictet Asset Management Holding SA lifted its position in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after purchasing an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock worth $39,086,000 after purchasing an additional 128,417 shares in the last quarter. Spruce Street Capital LP boosted its stake in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after purchasing an additional 326,081 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
KNSA has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Canaccord Genuity Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a report on Wednesday, October 28th. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $100.57.
Check Out Our Latest Research Report on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Featured Articles
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
